Robert B. Den, MD

Contact Dr. Den

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial
  2. Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy
  3. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences
  4. Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience
  5. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
  6. Rb/e2f1 as a master regulator of cancer cell metabolism in advanced disease
  7. A comparative study of PCS and PAM50 prostate cancer classification schemes
  8. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer
  9. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer
  10. Comparative genomics reveals distinct immune-oncologic pathways in African American Men with Prostate Cancer
  11. Radiopharmaceuticals for Bone Metastases
  12. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier
  13. Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice
  14. Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer
  15. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer[Formula presented]
  16. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
  17. Fractionation scheme and treatment planning method for early glottic cancer in the United States: Economic impact of different medical decisions
  18. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
  19. A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer
  20. Molecular biomarkers in localized prostate cancer: ASCO guideline
  21. Association of Presalvage Radiotherapy PSA Levels after Prostatectomy with Outcomes of Long-Term Antiandrogen Therapy in Men with Prostate Cancer
  22. Prognostic value of the SPOP mutant genomic subclass in prostate cancer
  23. Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer
  24. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis
  25. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance